Condition: Mature B-cell Non-Hodgkin Lymphoma · Sponsor: Children's Cancer Group, China
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
This description comes directly from the study's public registry record.
Yi-jin Gao · +82064 86-21-38626161 · gaoyijin@scmc.com.cn
Always discuss trial participation with your own doctor first.
| Shanghai Children's Medical Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07168980